AUGUST 28, 2025

Biophytis Receives EMA and Belgian Regulatory Approval to Initiate Phase 3 Sarcopenia Clinical Trial Biophytis announced that both Part I (European Medicines Agency scientific review) and Part II (Belgian national ethical assessment) of its Clinical Trial Application (CTA) for a Phase 3 study in sarcopenia have been successfully reviewed and accepted. With these approvals, Biophytis is now authorized to initiate patient enrollment for the Phase 3 sarcopenia trial at selected sites in Belgium. The company will also collaborate with leading clinical centers across additional European Member States under the harmonized European framework. “We are delighted to achieve both EMA and

Read the press release »

AUGUST 5, 2025

Biophytis Secures Non-Dilutive Bond Financing Line of up to €1 Million Biophytis announces the establishment of a non-dilutive bond financing line for a maximum amount of €1 million with Hexagon Capital Fund, with an initial subscription of €100,000. Fullscreen Mode

Read the press release »

JULY 30, 2025

Biophytis Joins Silver Innov’, an Incubator Dedicated to the Silver Economy Biophytis is relocating to Silver Innov, an incubator and business center specialized in innovation, healthcare, and aging. This move represents a key milestone in Biophytis’ strategic roadmap, reinforcing its presence within an ecosystem dedicated to the silver economy, healthy aging, and biopharmaceutical innovation. As of this July, Biophytis has moved into the Silver Innov’ premises in Ivry-sur-Seine, joining a dynamic community of companies focused on senior healthcare challenges. Silver Innov’ offers a flexible and connected working environment designed to foster synergies between academic, hospital, and industrial stakeholders, notably through

Read the press release »

JULY 16, 2025

Biophytis Wins Major Legal Victory Before the French Court of Cassation Biophytis announces a major legal victory. On July 9, 2025, the French Court of Cassation, the country’s highest judicial authority, issued a landmark ruling partially overturning the decision of the Paris Court of Appeal and ruling in favor of Biophytis in its legal dispute with Negma Group. Stanislas Veillet, CEO of Biophytis, stated: “This victory comes at a pivotal time for Biophytis. The decision of the Court of Cassation is a key milestone in defending the interests of Biophytis and its shareholders. It validates the company’s unwavering efforts and

Read the press release »

JULY 15, 2025

Biophytis Partners in AI with Lynx Analytics to Accelerate Drug Discovery for Sarcopenia Biophytis SA, a pioneering force in the development of transformative therapies for obesity, sarcopenia, and longevity, today announced a strategic partnership with Lynx Analytics, a pioneer in artificial intelligence solutions for life sciences. The collaboration aims to accelerate the discovery and development of novel small molecule drugs for the treatment of sarcopenia, a debilitating condition characterized by progressive loss of muscle mass and strength in old adults. Fullscreen Mode

Read the press release »

JULY 11, 2025

Biophytis Reports 2024 Financial Results and 2025 Outlook Plans to initiate Phase 2 study in obesity and Phase 3 study in sarcopenia as soon as possible. Continued partnership strategy to support the funding of clinical programs. Strengthening of the drug discovery platform through the integration of disruptive technologies. Biophytis announced its financial results for the year ended December 31, 2024, approved by its Board of Directors on July 9, 2025, and presented its strategic outlook. The Company also announces the resumption of trading of its shares on Euronext Growth Paris, effective at market open on July 11, 2025. Stanislas Veillet,

Read the press release »

JULY 8, 2025

Biophytis at the Forefront of Longevity Innovation at the World Aging & Rejuvenation Conference 2025 Biophytis announces its participation in the 7th edition of the World Aging & Rejuvenation Conference (ARC 2025), to be held in Vienna, Austria, from July 9 to 10, 2025. As part of this internationally renowned event dedicated to aging and longevity, Dr. Cendrine Tourette, Global project lead at Biophytis, will deliver an oral presentation entitled “Biophytis BIO101 in age-related sarcopenia: results of the SARA program” on July 9 at 4:40 PM. Her presentation will highlight the central role of Biophytis’ lead drug candidate BIO101 in

Read the press release »

JULY 7, 2025

Obesity: Biophytis Charts Its Course Toward a Booming Market Biophytis is seizing a major opportunity in the expanding obesity market by addressing an unmet medical need: preserving muscle mass and function in patients losing weight while treated with GLP-1 receptor agonists. GLP-1 therapies such as semaglutide and tirzepatide have revolutionized obesity management by enabling significant weight loss. However, up to 40% of total weight lost can come from muscle tissue, raising concerns about long-term mobility, strength, and metabolic health. Biophytis is at the forefront of this challenge with its lead drug candidate, BIO101 (20-hydroxyecdysone), the first oral MAS receptor activator

Read the press release »

JULY 3, 2025

Biophytis Powers Innovation in Obesity, Muscle Health, and Longevity at BIO International 2025 Biophytis is proud to announce its successful participation at the BIO International Convention 2025, the world’s largest and most comprehensive biotechnology event. Hosted at the Boston Convention & Exhibition Center from June 16-19, 2025, the convention gathered 20,000 industry leaders from across the globe, providing an unparalleled platform for collaboration, partnership, and scientific exchange. On this occasion, Biophytis engaged with global biopharma executives, investors, and research institutions, highlighting its robust pipeline and innovative approaches to addressing some of the most pressing health challenges of our time. The

Read the press release »

JUNE 30, 2025

Information on the Annual Financial Statements Biophytis announces that it is not in a position to publish its 2024 annual accounts on the previously scheduled date. Biophytis will publish its 2024 annual accounts as soon as possible, by Monday, July 7 at the latest. Fullscreen Mode

Read the press release »